The technology is set to eliminate the need for blood cartridges and decrease reliance on central labs, thereby easing the workload for hospital staff. Credit: PaeGAG / Shutterstock.

Inspira Technologies has expanded the usage of its blood sensor technology, HYLA, into a personalised blood lab test.

The test is designed to perform real-time blood work on the patient potentially detecting life-threatening conditions in a reduced period.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The business model of the technology seeks to streamline extracorporeal procedures by reducing the need for intermittent physical blood samples.

HYLA aims to simplify the process of blood testing in various medical settings, including emergency rooms, intensive care units, and operating theatres. It also has the potential to replace expensive equipment, eliminate the requirement for blood cartridges, and decrease reliance on central labs, thereby easing the workload for hospital staff.

Clinical evaluations of the technology are currently underway at Sheba Hospital, focusing on individuals undergoing open-heart surgeries.

These evaluations are part of the preparation for the company’s planned submission to the US Food and Drug Administration (FDA) for the first configuration of the HYLA next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Inspira Technologies CEO Dagi Ben-Noon said: “Our plans to use HYLA to perform blood work without the need to take physical blood samples is part of a broader business strategy.

“The core technologies of the INSPIRA ART are progressing, with the Company currently performing a clinical evaluation of the HYLA blood technology at Sheba hospital, with results expected to be revealed in the near future.”

Specialised in life support and respiratory treatment, Inspira has developed the Augmented Respiration Technology (INSPIRA ART).

This device is designed to rapidly stabilise oxygen saturation levels in patients with acute respiratory failure, offering an alternative to mechanical ventilators.

Equipped with the HYLA blood sensor, the INSPIRA ART aims to provide continuous monitoring and alert physicians to changes in a patient’s condition.

The INSPIRA ART100 system has already achieved 510(k) clearance from the FDA for use in cardiopulmonary bypass procedures and also obtained the Israeli Ministry of Health’s medical devices and accessories (AMAR) certification.